Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. A Phase 1a clinical trial has demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in humans. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
| Website | https://herantis.com/ |
| Ticker | HRTIS |
| Revenue | $1 million |
| Employees | 22 (13 on RocketReach) |
| Founded | 2008 |
| Address | 1 Bertel Jungin Aukio, Espoo, Uusimaa 02600, FI |
| Phone | +358 9 2221195 |
| Industry | Biotechnology Research, Manufacturing General, Biotechnology, Manufacturing, Science and Engineering, Clinical Trials, Health Care, Pharmaceutical |
| Web Rank | 3 Million |
| Keywords | Herantis Pharma, Lymfactin®, Finland Pharmaceuticals Distributors, Oncology Importers In Finland, Cdnf |
| Competitors | Roche, Pfizer, Amgen, Bristol Myers Squibb, Novartis, AbbVie, Sanofi, Regeneron, GSK, Merck AH +48 more (view full list) |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies |
Looking for a particular Herantis Pharma Plc. employee's phone or email?
Herantis Pharma Plc. Questions
The Herantis Pharma Plc. annual revenue was $1 million in 2026.
Antti Vuolanto is the CEO of Herantis Pharma Plc..
13 people are employed at Herantis Pharma Plc..
Herantis Pharma Plc. is based in Espoo, Uusimaa.
The NAICS codes for Herantis Pharma Plc. are [325, 32, 3254, 32541].
The SIC codes for Herantis Pharma Plc. are [283, 28].
Top Herantis Pharma Plc. Employees
Related Companies
